Tolerance of Healthy Term Infants Fed Infant Formulas #3

NCT ID: NCT00977964

Last Updated: 2010-11-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

270 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to assess the comparative gastrointestinal (GI) tolerance of normal term infants to six experimental milk protein-based powdered infant formulas.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastrointestinal Tolerance

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Infant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Milk Based Protein Formula Process A

Group Type EXPERIMENTAL

Experimental milk protein infant formula Process A

Intervention Type OTHER

ad lib for 1-8 days of age until 28 days of age

Milk Based Protein Formula Process B

Group Type EXPERIMENTAL

Experimental milk protein infant formula Process B

Intervention Type OTHER

ad lib from 1-8 days of age until 28 days of age

Milk Based Protein Formula Process C

Group Type EXPERIMENTAL

Experimental milk protein infant formula Process C

Intervention Type OTHER

ad lib from 1-8 days of age to 28 days of age

Milk Based Protein Formula Process D

Group Type EXPERIMENTAL

Experimental milk protein infant formula Process D

Intervention Type OTHER

ad lib from 1-8 days of age until 28 days of age

Milk Based Protein Formula Process E

Group Type EXPERIMENTAL

Experimental milk protein infant formula Process E

Intervention Type OTHER

ad lib from 1-8 days of age until 28 days of age

Milk Based Protein Formula Process F

Group Type EXPERIMENTAL

Experimental milk protein infant formula Process F

Intervention Type OTHER

ad lib from 1-8 days of age until 28 days of age

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental milk protein infant formula Process A

ad lib for 1-8 days of age until 28 days of age

Intervention Type OTHER

Experimental milk protein infant formula Process B

ad lib from 1-8 days of age until 28 days of age

Intervention Type OTHER

Experimental milk protein infant formula Process C

ad lib from 1-8 days of age to 28 days of age

Intervention Type OTHER

Experimental milk protein infant formula Process D

ad lib from 1-8 days of age until 28 days of age

Intervention Type OTHER

Experimental milk protein infant formula Process E

ad lib from 1-8 days of age until 28 days of age

Intervention Type OTHER

Experimental milk protein infant formula Process F

ad lib from 1-8 days of age until 28 days of age

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infant is judged to be in good health.
* Infant is a singleton from a full term birth.
* Infant's birth weight was \> 2490 g (\~5 lbs 8 oz.
* Infant is between 0 and 8 days of age at enrollment.
* Infants using medications, home remedies ,herbal preparations or rehydration fluids that might affect GI tolerance may not be enrolled.
* Parent(s) confirm their intention not to administer vitamin or mineral supplements, solid foods or juices to their infant from enrollment through the duration of the study, unless instructed otherwise by their healthcare professional.

Exclusion Criteria

* An adverse maternal, fetal or infant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development.
* Infant has been treated with antibiotics.
* Infant has received probiotics.
Maximum Eligible Age

8 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Nutrition

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Abbott Nutrition

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Caude T Ashley, MD

Role: PRINCIPAL_INVESTIGATOR

Alabama Clinical Therapeutics, LLC

Terri L Ashmeade, MD

Role: PRINCIPAL_INVESTIGATOR

USF Department of Pediatrics

Jay Cohen, MD

Role: PRINCIPAL_INVESTIGATOR

Discovery Clinical Research, Inc.

Timothy Crum, MD

Role: PRINCIPAL_INVESTIGATOR

Rockwood Clinic

Cole Ezeoke, MD

Role: PRINCIPAL_INVESTIGATOR

North Georgia Clinical Research, White's Pediatrics

Sharon Groh-Wargo, PhD, RD, LD

Role: PRINCIPAL_INVESTIGATOR

MetroHealth Medical Center

James Guerrieri, MD

Role: PRINCIPAL_INVESTIGATOR

Institute of Clinical Research, LLC

James Hedrick, MD

Role: PRINCIPAL_INVESTIGATOR

Kentucky Pediatric Research

Jeffrey Hirschfield, MD

Role: PRINCIPAL_INVESTIGATOR

SCORE Physician Alliance, LLC

Kevin Mullen, MD

Role: PRINCIPAL_INVESTIGATOR

Medical Associates Clinic, PC

Chris Peltier, MD

Role: PRINCIPAL_INVESTIGATOR

Pediatric Associates of Mount Carmel, Inc.

Martin J Schear, MD

Role: PRINCIPAL_INVESTIGATOR

Dayton Clinical Research

Julie Shepard, MD

Role: PRINCIPAL_INVESTIGATOR

Ohio Pediatric Research Association

William Stepp, MD

Role: PRINCIPAL_INVESTIGATOR

Sarah Cannon Research Institute, LLC

L Louise Tetrick, MD

Role: PRINCIPAL_INVESTIGATOR

Northpoint Pediatrics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Clinical Therapeutics

Dothan, Alabama, United States

Site Status

All Women's Heatlthcare of West Broward, Inc: Discovery Clinical Research, Inc

Plantation, Florida, United States

Site Status

SCORE Physician Alliance, LLC

St. Petersburg, Florida, United States

Site Status

University of South Florida

Tampa, Florida, United States

Site Status

North Georgia Clinical Research

Dalton, Georgia, United States

Site Status

Northpoint Pediatrics, LLC

Indianapolis, Indiana, United States

Site Status

Medical Associates Clinic, PC

Dubuque, Iowa, United States

Site Status

Kentucky Pediatric / Adult Research

Bardstown, Kentucky, United States

Site Status

Pediatric Associates of Mount Carmel, Inc

Cincinnati, Ohio, United States

Site Status

MetroHealth Medical Center

Cleveland, Ohio, United States

Site Status

Dayton Clinical Research

Dayton, Ohio, United States

Site Status

Ohio Pediatric Research Association, Inc.

Huber Heights, Ohio, United States

Site Status

Institute of Clinical Research

Mayfield Heights, Ohio, United States

Site Status

The Jackson Clinic, PA

Jackson, Tennessee, United States

Site Status

Rockwood Clinic North - Pediatrics

Spokane, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Gonzalez-Garay AG, Serralde-Zuniga AE, Medina Vera I, Velasco Hidalgo L, Alonso Ocana MV. Higher versus lower protein intake in formula-fed term infants. Cochrane Database Syst Rev. 2023 Nov 6;11(11):CD013758. doi: 10.1002/14651858.CD013758.pub2.

Reference Type DERIVED
PMID: 37929831 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AK70

Identifier Type: -

Identifier Source: org_study_id